NASDAQ:EYES - Second Sight Medical Products Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.76 +0.03 (+1.73 %)
(As of 06/22/2018 04:00 PM ET)
Previous Close$1.73
Today's Range$1.68 - $1.77
52-Week Range$0.90 - $2.58
Volume345,500 shs
Average Volume497,258 shs
Market Capitalization$119.94 million
P/E Ratio-2.85
Dividend YieldN/A
Second Sight Medical Products logoSecond Sight Medical Products, Inc., together with its subsidiaries, develops, manufactures, and markets prosthetic devices to restore functional vision of blind individuals in the United States, Canada, Europe, the Middle East, and Asia. It offers Argus II System, which treats outer retinal degenerations, such as retinitis pigmentosa. The company was formerly known as Second Sight LLC. and changed its name to Second Sight Medical Products, Inc. Second Sight Medical Products, Inc. was founded in 1998 and is headquartered in Sylmar, California.

Receive EYES News and Ratings via Email

Sign-up to receive the latest news and ratings for EYES and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Electromedical equipment


Debt-to-Equity RatioN/A
Current Ratio1.33
Quick Ratio0.92


Trailing P/E Ratio-2.85
Forward P/E Ratio-3.14
P/E GrowthN/A

Sales & Book Value

Annual Sales$7.96 million
Price / Sales14.73
Cash FlowN/A
Price / CashN/A
Book Value$0.14 per share
Price / Book12.57


EPS (Most Recent Fiscal Year)($0.59)
Net Income$-28,510,000.00
Net Margins-387.35%
Return on Equity-307.76%
Return on Assets-194.77%


Outstanding Shares66,630,000

Second Sight Medical Products (NASDAQ:EYES) Frequently Asked Questions

What is Second Sight Medical Products' stock symbol?

Second Sight Medical Products trades on the NASDAQ under the ticker symbol "EYES."

How were Second Sight Medical Products' earnings last quarter?

Second Sight Medical Products Inc (NASDAQ:EYES) issued its quarterly earnings data on Thursday, May, 10th. The medical device company reported ($0.17) EPS for the quarter. The medical device company had revenue of $0.98 million for the quarter. Second Sight Medical Products had a negative net margin of 387.35% and a negative return on equity of 307.76%. View Second Sight Medical Products' Earnings History.

When is Second Sight Medical Products' next earnings date?

Second Sight Medical Products is scheduled to release their next quarterly earnings announcement on Monday, July, 30th 2018. View Earnings Estimates for Second Sight Medical Products.

What price target have analysts set for EYES?

1 Wall Street analysts have issued 1-year price targets for Second Sight Medical Products' stock. Their forecasts range from $5.00 to $5.00. On average, they anticipate Second Sight Medical Products' share price to reach $5.00 in the next year. View Analyst Ratings for Second Sight Medical Products.

What are Wall Street analysts saying about Second Sight Medical Products stock?

Here are some recent quotes from research analysts about Second Sight Medical Products stock:
  • 1. According to Zacks Investment Research, "Second Sight Medical Products, Inc. is a medical device company. It develops, manufactures, and markets implantable prosthetic devices to restore some functional vision to blind patients. The Company provides Argus II system, an implantable neurostimulation device for the treatment of outer retinal degenerations, such as retinitis pigmentosa. Second Sight Medical Products, Inc. is headquartered in Sylmar, California. " (5/17/2018)
  • 2. HC Wainwright analysts commented, "We expect that the second pilot study could start in late 3Q17 or early 4Q17 and report top-line data by the end of 2017. Investors may recall that this second pilot study is double-masked and slated to enroll up to 45 subjects. The primary endpoint is the percentage of subjects achieving complete wound healing (based on staining) on day 3. Assuming that the second pilot study shows OBG’s ability to heal corneal defects faster than the standard of care, as was seen in the first pilot study, we believe that EyeGate may only need to conduct a single pivotal study in 2018 before filing for regulatory approval. We note that the FDA has permitted EyeGate to pursue U.S. regulatory clearance for OBG through the de novo 510(k) pathway." (8/8/2017)

Who are some of Second Sight Medical Products' key competitors?

Who are Second Sight Medical Products' key executives?

Second Sight Medical Products' management team includes the folowing people:
  • Mr. Stephen D. Okland Jr., Chief Commercial Officer (Age 54)
  • Mr. Jonathan Will McGuire, Chief Exec. Officer, Pres and Director (Age 55)
  • Gunnar Bjorg, Founder
  • Mr. John T. Blake, CFO & Corp. Sec. (Age 42)

When did Second Sight Medical Products IPO?

(EYES) raised $32 million in an initial public offering (IPO) on Wednesday, November 19th 2014. The company issued 3,500,000 shares at $9.00 per share. MDB Capital Group, LLC acted as the underwriter for the IPO.

Has Second Sight Medical Products been receiving favorable news coverage?

Headlines about EYES stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Second Sight Medical Products earned a daily sentiment score of 0.22 on Accern's scale. They also gave media headlines about the medical device company an impact score of 45.38 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Who are Second Sight Medical Products' major shareholders?

Second Sight Medical Products' stock is owned by many different of retail and institutional investors. Top institutional investors include Glassman Wealth Services (0.12%). Company insiders that own Second Sight Medical Products stock include Edward David Randolph, Gregg Williams, Jonathan Will Mcguire, Robert J Greenberg and Stephen D Okland. View Institutional Ownership Trends for Second Sight Medical Products.

Which major investors are buying Second Sight Medical Products stock?

EYES stock was purchased by a variety of institutional investors in the last quarter, including Glassman Wealth Services. View Insider Buying and Selling for Second Sight Medical Products.

How do I buy shares of Second Sight Medical Products?

Shares of EYES can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Second Sight Medical Products' stock price today?

One share of EYES stock can currently be purchased for approximately $1.76.

How big of a company is Second Sight Medical Products?

Second Sight Medical Products has a market capitalization of $119.94 million and generates $7.96 million in revenue each year. The medical device company earns $-28,510,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis. Second Sight Medical Products employs 112 workers across the globe.

How can I contact Second Sight Medical Products?

Second Sight Medical Products' mailing address is 12744 SAN FERNANDO ROAD SUITE 400, SYLMAR CA, 91342. The medical device company can be reached via phone at 818-833-5000 or via email at [email protected]

MarketBeat Community Rating for Second Sight Medical Products (EYES)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  133 (Vote Outperform)
Underperform Votes:  128 (Vote Underperform)
Total Votes:  261
MarketBeat's community ratings are surveys of what our community members think about Second Sight Medical Products and other stocks. Vote "Outperform" if you believe EYES will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYES will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/22/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.